Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually le⦠read more
Healthcare
Biotechnology
2 years
USD
Exclusive to Premium users
$6.02
Price-11.41%
-$0.77
$342.543m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$588k
-
1y CAGR-
3y CAGR-
5y CAGR-$63.488m
-
1y CAGR-
3y CAGR-
5y CAGR-$1.12
-
1y CAGR-
3y CAGR-
5y CAGR$213.037m
$222.886m
Assets$9.849m
Liabilities$1.102m
Debt0.5%
-
Debt to EBITDA-$50.779m
-
1y CAGR-
3y CAGR-
5y CAGR